Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 1-Year High Following Analyst Upgrade

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) shares reached a new 52-week high on Wednesday after Wells Fargo & Company raised their price target on the stock from $22.00 to $30.00. Wells Fargo & Company currently has an overweight rating on the stock. Monte Rosa Therapeutics traded as high as $23.90 and last traded at $23.1810, with a volume of 8689159 shares changing hands. The stock had previously closed at $16.01.

A number of other research analysts also recently weighed in on the stock. Wedbush reissued an “outperform” rating and set a $37.00 target price on shares of Monte Rosa Therapeutics in a research report on Wednesday. Jefferies Financial Group reissued a “buy” rating and set a $31.00 price objective on shares of Monte Rosa Therapeutics in a report on Wednesday. Zacks Research upgraded Monte Rosa Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research report on Monday, December 29th. Finally, Cowen reissued a “buy” rating on shares of Monte Rosa Therapeutics in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $30.20.

Monte Rosa Therapeutics News Roundup

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: MRT-8102 interim Phase 1 data show rapid, deep and durable NEK7 degradation with an 85% median hsCRP reduction after four weeks in subjects with elevated CVD risk; safety profile described as favorable. The company is expanding the GFORCE-1 study and plans a Phase 2 (GFORCE-2) in 2026. Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102
• Positive Sentiment: Market reaction: multiple outlets report a sharp share move after the data (Zacks/Investing/MSN coverage highlighted the CRP results), driving short‑term buying and momentum flows. GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
• Positive Sentiment: Analyst upgrades and price-target hikes: Wells Fargo raised its target to $30 with an Overweight call and Guggenheim raised its target to $34 with a Buy — these lifts help validate the data and give brokers’ clients a reason to buy. Benzinga coverage of analyst actions
• Positive Sentiment: Zacks upgraded GLUE to a Strong Buy (Zacks Rank #1), increasing visibility among quant and momentum-driven retail investors. Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy
• Neutral Sentiment: Commentary pieces highlight that the price trend could be sustainable given the clinical readout and upcoming milestones, but note further validation will depend on larger/longer studies and the H2 2026 GFORCE‑1 readout. Monte Rosa Therapeutics (GLUE) is on the Move
• Negative Sentiment: Monte Rosa announced a proposed $200M underwritten public offering of common stock and pre-funded warrants — this raises near-term dilution risk and could cap upside until proceeds are deployed or absorbed. Monte Rosa Therapeutics Announces Proposed Public Offering

Institutional Trading of Monte Rosa Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC grew its holdings in Monte Rosa Therapeutics by 20.2% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,289 shares of the company’s stock valued at $357,000 after buying an additional 3,746 shares in the last quarter. GAMMA Investing LLC bought a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at about $30,000. Vestal Point Capital LP purchased a new stake in shares of Monte Rosa Therapeutics in the third quarter worth about $5,928,000. Scientech Research LLC bought a new position in shares of Monte Rosa Therapeutics in the third quarter valued at approximately $120,000. Finally, Prelude Capital Management LLC bought a new position in shares of Monte Rosa Therapeutics in the third quarter valued at approximately $76,000. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Price Performance

The firm’s 50 day moving average is $15.78 and its 200 day moving average is $9.60. The company has a market cap of $1.65 billion, a PE ratio of 79.10 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.06. The firm had revenue of $12.77 million during the quarter, compared to the consensus estimate of $7.37 million. Monte Rosa Therapeutics had a net margin of 11.54% and a return on equity of 8.28%. As a group, analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current year.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.